SAN ANTONIO--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced the presentation of preliminary results from a single-arm, open-label, Phase II clinical trial evaluating ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin- bound) in combination with gemcitabine and epirubicin for the treatment of patients with locally advanced breast cancer (neoadjuvant treatment). In the preliminary analysis, 18 percent of patients (n=23) given a regimen of ABRAXANE (nab™-paclitaxel), gemcitabine and epirubicin achieved a complete pathologic response (the disappearance of all target lesions), and 68 percent (n=84) achieved a partial response (a 30 percent or greater decrease in size of target lesions). The findings were presented during the CTRC-AACR San Antonio Breast Cancer Symposium.
